Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma

Gunnarsson, Orvar; Pfanzelter, Nicklas R.; Cohen, Roger B.; Keefe, Stephen M.
February 2015
Cancer Management & Research;2015, Vol. 7, p65
Academic Journal
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor-α, and c-kit. Phase I studies demonstrated 5 mg twice daily as the recommended starting dose with notable effects seen in renal cell carcinoma, an observation confirmed in Phase II trials. The trial of comparative effectivess of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) was an international randomized Phase III study designed for registration purposes, compared axitinib to sunitinib. This trial randomized 723 patients with metastatic kidney cancer to axitinib or sunitinib in the second-line setting and demonstrated a median progression-free survival of 6.7 months for axitinib versus 4.7 months for sorafenib (P,0.0001). Clinical benefit was detected regardless of prior therapy, but no overall survival benefit has been observed. Axitinib is well tolerated without a significant effect on quality of life. The most common grade 3 toxicities are hypertension (16%), diarrhea (11%), and fatigue (11%), with other notable side effects being anorexia, nausea, hand-foot syndrome, and rash. Patients who developed diastolic blood pressure >90 mmHg were noted to have significantly longer median overall survival and overall response rates when compared to normotensive patients. Therefore, the manufacturer recommends escalating the twice-daily dose to 7 mg and 10 mg, as tolerated, if there is no significant increase in blood pressure on treatment. Currently, axitinib is approved for use in the second-line setting for patients with metastatic renal cell carcinoma. Research is ongoing in other disease settings.


Related Articles

  • Targeted treatments in advanced renal cell carcinoma: focus on axitinib. Verzoni, Elena; Grassi, Paolo; Testa, Isabella; Iacovelli, Roberto; Biondani, Pamela; Garanzini, Enrico; De Braud, Filippo; Procopio, Giuseppe // Pharmacogenomics & Personalized Medicine;2014, Vol. 7, p107 

    Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal...

  • Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Koh, Y.; Lim, H. Y.; Ahn, J. H.; Lee, J.-L.; Rha, S. Y.; Kim, Y. J.; Kim, T. M.; Lee, S.-H. // Annals of Oncology;Apr2013, Vol. 24 Issue 4, p1026 

    Background We investigated the efficacy of everolimus against nonclear-cell renal cell carcinoma (nccRCC). Patients and methods Patients with nccRCC received 10-mg everolimus once daily until disease progression or unacceptable toxicity. Patients who had received a VEGF- tyrosine kinase...

  • Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Narayan, Vivek; Haas, Naomi Balzer // International Journal of Nephrology & Renovascular Disease;Mar2016, Vol. 9, p65 

    Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the...

  • Renal Cancer.  // Current Medical Literature: Urology;2010, Vol. 16 Issue 2, p58 

    The article discusses a research study which summarized the evidence supporting the use of the new therapeutic approaches in renal cell carcinoma (RCC). It references a study by G. Facchini et al, published in a 2009 issue of the journal "Anticancer Drugs." It mentions previous treatments for...

  • The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Algazi, A P; Cha, E; Ortiz-Urda, S M; McCalmont, T; Bastian, B C; Hwang, J; Pampaloni, M H; Behr, S; Chong, K; Cortez, B; Quiroz, A; Coakley, F; Liu, S; Daud, A I // British Journal of Cancer;4/14/2015, Vol. 112 Issue 8, p1326 

    Background:Simultaneous chemotherapy with vascular endothelial growth factor (VEGF) inhibition has not shown additional benefit over chemotherapy alone in advanced melanoma. We tested administration of the potent VEGF inhibitor axitinib followed by paclitaxel/carboplatin to determine whether...

  • A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Strosberg, J. R.; Weber, J. M.; Choi, J.; Campos, T. L.; Valone, T. L.; Han, G.; Schell, M. J.; Kvols, L. K. // Annals of Oncology;Sep2012, Vol. 23 Issue 9, p2335 

    Background The liver is the predominant site of metastases among patients with advanced neuroendocrine tumors (NETs). Prior retrospective studies have reported high response rates in patients treated with transarterial embolization (TAE). NETs are highly vascular and are known to express...

  • The Clear Cell RCC Paradigm. Srinivasan, Ramaprasad; Linehan, W. Marston // AUANews;Apr2007, Vol. 12 Issue 4, p8 

    The article presents findings of clinical trials for therapeutic agents used in the treatment of clear cell renal cell carcinoma (RCC). According to the authors, these trials also helped in identifying the familial kidney cancer syndrome called von Hippel Lindau disease (VHL). Some of the...

  • Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment. Michalaki, Vasiliki; Arkadopoulos, Nikolaos; Kondi-Pafiti, Agathi; Gennatas, Constantine // World Journal of Surgical Oncology;2010, Vol. 8, p45 

    Background: Renal cell carcinoma (RCC) represents approximately 3% of all adult cancers and is more common in males. Systemic treatment for RCC has improved following the introduction of tyrosine kinase inhibitors, such as sunitinib. The molecular targets of sunitinib are receptor tyrosine...

  • Tivozanib in the treatment of renal cell carcinoma. Hepgur, Mehmet; Sadeghi, Sarmad; Dorff, Tanya B.; Quinn, David I. // Biologics: Targets & Therapy;2013, Vol. 7, p139 

    Renal cell carcinoma (RCC) is an aggressive malignancy compared to other urological malignancies and has been associated with poor responses to conventional cytotoxic chemotherapy. Interferon-α and interleukin-2 were previously utilized in a limited number of patients with good performance...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics